[63] found in pancreatic cancer that neoadjuvant therapy can induce upregulation of complement components, including C1R, in the TME, thereby alleviating immune cell exhaustion and enhancing its response to immunotherapy. The gene discussed is C1R; the disease is familial pancreatic carcinoma.